Molecular based methods have advanced the centre testing to faster and better diagnostics. PCR methods, microarray and next generation sequencing have provided speed and
high level of accuracy. Molecular biology based methods are sensitive and quick to detect microbial pathogens in various clinical specimens.
We offer molecular detection of pathogenic viruses, bacteria and parasites from clinical specimens. MBG is ISO 15189 accredited and benefits from a stand-alone
containment Level 3 facility where samples for highly contagious pathogen are received and processed.
Aspergillus is a type of fungus that is found indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, health problems may arise in people with weakened immune systems or having underlying diseases.
Aspergillosis, most often caused by Aspergillus fumigatus, occurs in humans in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in people with severely compromised immune systems, e.g. those undergoing bone marrow transplantation. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses, such as asthma, cystic fibrosis, sarcoidosis, tuberculosis, or chronic obstructive pulmonary disease. The most frequently identified pathogens are Aspergillus fumigatus and Aspergillus flavus, ubiquitous organisms capable of living under extensive environmental stress.
Aspergillus fumigatus is the primary cause of invasive aspergillosis. Triazole antifungals are used to treat patients with high-risk conditions such as stem cell and organ transplant recipients as mortality exceeds 50%. However, triazole-resistant A. fumigatus infections frequently occur and are associated with increased treatment failure and mortality. Of particular concern are resistant A.fumigatus isolates carrying either TR34/L98H or TR46/Y121F/T289A genetic resistance markers in the azole target (Cyp51A) gene and these are mostly associated with triazole fungicide use. Reports of these triazole-resistant A.fumigatus strains are more common in Europe than in the US.Understanding the prevalence of azole resistant patient isolates is important to guide clinical and public health decision-making.
Pathogens Tested
HPA-098 : Aspergillus fumigatus/ terreus/ flavus
HPA-189 : Azole-resistance profiling of Cyp51A gene
Method
Aspergillus fumigatus / terreus / flavus by Multi Real-Time PCR (This assay includes the detection and differentiation of Aspergillus fumigatus / terreus / flavus) Azole-resistance profiling of Cyp51A gene (This assay detects selected mutations in the Cyp51A gene related to azole-resistance, by PCR and sequencing).
TAT for routine samples is within 10 working days. Urgent Samples will be charged double and will be reported within 7 working days.
Samples delivered before 11:00 AM will begin processing immediately resulting in shorter TAT.
Molecular based methods have advanced the centre testing to faster and better diagnostics. PCR methods, microarray and next generation sequencing have provided speed and
high level of accuracy. Molecular biology based methods are sensitive and quick to detect microbial pathogens in various clinical specimens.
We offer molecular detection of pathogenic viruses, bacteria and parasites from clinical specimens. MBG is ISO 15189 accredited and benefits from a stand-alone
containment Level 3 facility where samples for highly contagious pathogen are received and processed.
Aspergillus is a type of fungus that is found indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, health problems may arise in people with weakened immune systems or having underlying diseases.
Aspergillosis, most often caused by Aspergillus fumigatus, occurs in humans in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in people with severely compromised immune systems, e.g. those undergoing bone marrow transplantation. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses, such as asthma, cystic fibrosis, sarcoidosis, tuberculosis, or chronic obstructive pulmonary disease. The most frequently identified pathogens are Aspergillus fumigatus and Aspergillus flavus, ubiquitous organisms capable of living under extensive environmental stress.
Aspergillus fumigatus is the primary cause of invasive aspergillosis. Triazole antifungals are used to treat patients with high-risk conditions such as stem cell and organ transplant recipients as mortality exceeds 50%. However, triazole-resistant A. fumigatus infections frequently occur and are associated with increased treatment failure and mortality. Of particular concern are resistant A.fumigatus isolates carrying either TR34/L98H or TR46/Y121F/T289A genetic resistance markers in the azole target (Cyp51A) gene and these are mostly associated with triazole fungicide use. Reports of these triazole-resistant A.fumigatus strains are more common in Europe than in the US.Understanding the prevalence of azole resistant patient isolates is important to guide clinical and public health decision-making.
Pathogens Tested
HPA-098 : Aspergillus fumigatus/ terreus/ flavus
HPA-189 : Azole-resistance profiling of Cyp51A gene
Method
Aspergillus fumigatus / terreus / flavus by Multi Real-Time PCR (This assay includes the detection and differentiation of Aspergillus fumigatus / terreus / flavus) Azole-resistance profiling of Cyp51A gene (This assay detects selected mutations in the Cyp51A gene related to azole-resistance, by PCR and sequencing).
TAT for routine samples is within 10 working days. Urgent Samples will be charged double and will be reported within 7 working days.
Samples delivered before 11:00 AM will begin processing immediately resulting in shorter TAT.
